Non-coding RNAs in renal cell carcinoma: Implications for drug resistance

Biomed Pharmacother. 2023 Aug:164:115001. doi: 10.1016/j.biopha.2023.115001. Epub 2023 Jun 12.

Abstract

Renal cell carcinoma (RCC) represents a malignant tumor of the urinary system. Individuals with early-stage RCC could be cured by surgical treatment, but a considerable number of cases of advanced RCC progress to drug resistance. Recently, numerous reports have demonstrated that a variety of non-coding RNAs (ncRNAs) contribute to tumor occurrence and development. ncRNAs can act as oncogenic or tumor suppressor genes to regulate proliferation, migration, drug resistance and other processes in RCC cells through a variety of signaling pathways. Considering the lack of treatment options for advanced RCC after drug resistance, ncRNAs may be a good choice as biomarkers of drug resistance in RCC and targets to overcome drug resistance. In this review, we discussed the effects of ncRNAs on drug resistance in RCC and the great potential of ncRNAs as a biomarker of or a new therapeutic method in RCC.

Keywords: Biomarkers; Drug resistance; MiRNAs; Non-coding RNAs; Renal cell carcinoma.

Publication types

  • Review

MeSH terms

  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / genetics
  • Carcinoma, Renal Cell* / pathology
  • Drug Resistance
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / genetics
  • Kidney Neoplasms* / pathology
  • RNA, Long Noncoding*
  • RNA, Untranslated / genetics
  • Signal Transduction

Substances

  • RNA, Untranslated
  • RNA, Long Noncoding